



MiCheck[®] Prostate – Update

BioShares 2025

August 2025

Brad Walsh, CEO brad.walsh@minomoic.com

Important Notices and Disclaimer

This Presentation has been prepared by Minomic International Ltd ACN 124 455 081 ("Minomic") and is intended only for those persons to whom it is delivered personally by or on behalf of Minomic. "Presentation" means and includes this document, any oral presentation by Minomic, or any person on its behalf, any question-and-answer session that may follow the oral presentation, and any materials distributed in connection therewith.

No offer, advice or recommendation

This Presentation contains summary information about Minomic and Minomic's activities which is current at the date of this Presentation (unless otherwise noted). This Presentation is for informational purposes, is not a prospectus or other disclosure document and does not constitute or form part of, and should not be construed as, an offer to sell or issue securities or otherwise constitute an invitation or inducement and is not part of any contract or commitment for a person to purchase, underwrite, subscribe to or otherwise acquire securities in Minomic.

In particular, this Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any 'U.S. person' as defined in Rule 902(k) under the U.S. Securities Act of 1933, as amended (US Securities Act) (US Person). The securities to be offered and sold in the equity private placement described in this Presentation have not been, and will not be, registered under the US Securities Act or the securities laws of any state or other jurisdiction of the United States. Accordingly, such securities may not be offered and sold, directly or indirectly, to any person in the United States or any person that is, or is acting for the account or benefit of, a US Person, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and any applicable US state securities laws.

Nothing contained in this Presentation constitutes financial product, investment, legal, tax or other advice. It does not take into account the investment objectives, financial situation or needs of any particular investor. All recipients should consider the appropriateness of the information in this Presentation having regard to their own investment objectives, financial situation and needs and whether professional advice is required, when deciding if an investment is appropriate.


No reliance

To the maximum extent permitted by law, neither Minomic, nor any of their officers, employees, representatives, related bodies corporate, affiliates, partners, shareholders, agents or advisers guarantees or makes any representations or warranties, express or implied, as to, or takes responsibility for, the accuracy or reliability of the information contained in this Presentation or as to any other matter. Nothing contained in this Presentation, nor any information made available in connection with it is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or the future. The parties have not carried out independent verification or any form of due diligence investigations in connection with the preparation of this Presentation. To the extent permitted by law, none of the parties takes any responsibility for any loss or damage suffered as a result of any inadequacy, incompleteness or inaccuracy in any such statement or information. To the extent permitted by law, the parties do not accept any liability to any person for any direct, indirect or consequential loss or damage arising from the use of this Presentation.

None of the Sponsor's advisers have authorised, permitted or caused the issue, lodgement, submission, dispatch or provision of this Presentation, make or purport to make any statement in this Presentation and there is no statement in this Presentation which is based on any statement by any of them.

MiCheck[®] Prostate **is a next-generation blood test for** **clinically significant prostate cancer risk**

MiCheck® Test Components and Workflow



MiCheck® Prostate Outperforms Competitors

Manufacturer	Specimen	Sensitivity	Specificity	NPV	PPV
Minomic	Blood	95%	62%	96% for GS \geq 3+4 99% for GS \geq 4+3	53%
OPKO 4kScore	Blood	95%	27%	Optimal cutoff not calculated	Optimal cutoff not calculated
Exosome	Urine	90%	34%	91% for GS 7	35%
IsoPSA	Blood	90%	48%	87%	55%

Reimbursement Code Now Achieved – From 1 Oct 25



CPT® Proprietary Laboratory Analyses (PLA) Codes: Long Descriptors

Proprietary Name and Clinical Laboratory and/or Manufacturer	Code	Long Code Descriptor	Released to AMA Website	Effective Date	Publication
MiCheck® Prostate, Minomic®, Inc, Minomic®, Inc	●0591U	Oncology (prostate cancer), biochemical analysis of 3 proteins (total PSA, free PSA, and HE4), plasma, serum, prognostic algorithm incorporating 3 proteins and digital rectal examination, results reported as a probability score for clinically significant prostate cancer	July 1, 2025	October 1, 2025	CPT® 2026

Who is Doc Lab?

- **Doc Lab** – A proven partner in Urology Dx
 - U.S.-based diagnostic services company focused on **urology practices and Physician Office Labs (POLs)**
 - Owner of **SoftCell Laboratories**, a CLIA-certified reference lab in Saint George, Utah
 - Track record of launching and scaling diagnostics with a **6–12 month revenue ramp**

Market Footprint:



- Relationships with over 100 urology groups
- Active presence in **25+ states**
- Access to more than **2,000 urologists**, including LUGPA-affiliated and high-volume private practices
- Proven experience integrating tests into **over 50 POLs** and multiple reference laboratories



Our Two Sales Channel Approach

Commercial Execution Across ~4,000+ urology practices

Direct to Physician Channel – SoftCell Lab	POL Channel
<p>LUGPA's</p> <ul style="list-style-type: none">• Focused on reducing unnecessary biopsies• Open to adopting decision-support tools <p>145+ groups, 2200+ urologists, 35% of U.S Urology Care</p> <p>Community Urologists</p> <ul style="list-style-type: none">• Reimbursement-driven decisions• Potential for value-based care integration <p>~2,500+ are independently owned</p> <p>Academic/Speciality Centres</p> <ul style="list-style-type: none">• Research driver, KOL influence• Ideal for pilot studies <p>~400+ academic centers</p>	<p>Practices with High-Complexity CLIA Labs</p> <ul style="list-style-type: none">• Early adopters• Alternate revenue channels <p>~500+ POLs</p>

Exclusivity & Revenue Model

- Structure
 - Exclusive U.S. commercial rights granted to Doc Lab subject to minimum sales volume
 - 3-year agreement, with structured review at the end of the term
- Revenue Model
 - Softcell (Reference Lab Channel): Gross revenue split
 - POL Channel: Flat fee per MiCheck® Prostate test

Year	Forecast Volume (Tests)	Minomic Revenue (USD)
'25 – '26	21,000	\$3.8M
'26 – '27	66,000	\$12.0M
'27 – '28	138,000	\$25.7M

Currently raising capital with Carche Pty Ltd to fund our efforts

Leadership Team



**Founder/Group CEO –
Dr. Brad Walsh**

- 30+ years in Biotech Industry
- Founder of multiple companies
- Co-inventor of IP
- Raised equity and non dilutive funding to commercialise MiCheck®



**Group COO and Minomic Inc CEO –
Sushmita Utpala**

- 20+ years in Biotech industry
- GTM Strategy
- Revenue Growth
- Ex-Decipher (Veracyte)/ Genentech

Senior Team



David Burdis
Chief Financial Officer/
Company Secretary



Dr Douglas Campbell
Head of Research
and Development



Carl Stubbings
Chief Commercial
Officer



Dr Yanling Lu
Head of CMC



Dr. Chih-Ling Zao
US Lab Director





Thank You

Minomic International Ltd
www.micheckprostate.com
www.minomic.com